Optivol Diagnostic Data for Discharge in Heart Failure
Sponsored by Thomas Jefferson University
About this trial
Last updated 15 years ago
Study ID
06U.232
Status
Completed
Type
Observational
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 15 years ago
What is this trial about?
The objective of this study is to evaluate whether the heart rate variability, daily heart
rate, and/or intrathoracic impedance recorded by implantable cardiac devices can be used in
conjunction with other traditional clinical practice methods to determine if heart failure
patients are ready for hospital discharge.
What are the participation requirements?
Inclusion Criteria
- Patients implanted with a Medtronic InSync Sentry or subsequent FDA-approved Medtronic device with the OptiVol capability for >30 days.
- Anticipated hospitalization stay >48 hours
- Hospitalized patients experiencing worsening heart failure with symptoms of lung/pulmonary congestion.
Exclusion Criteria
- Anemia - admission hemoglobin <8.0 g/dL
- Patients residing in convalescence center prior to admission or known to be discharged to a convalescence center or hospice, where discharge could be based on bed availability